Previous Close | 33.22 |
1-Year Change | 23.96% |
6-Months Change | -26.23% |
3-Months Change | -37.19% |
Moving Avg (50d) | 37.266 |
Moving Avg (200d) | 42.867 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 1.9B |
Beta (3-Years) | 1.46 |
Revenue Growth (ttm) | 36.07% |
Net Profit Margin (ttm) | 1845.92% |
Return On Assets (ttm) | 40.51% |
EPS (ttm) | 11.34 |
PE Ratio (ttm) | 2.93 |
Dividend Yield | % |
Asset Description: | Agios Pharmaceuticals, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-12-16 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
32.556 | 31.559 | 30.895 | 29.898 | 28.237 | 26.576 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |